Bristol Myers Squibb was CytomX Therapeutics’s largest revenue line in fiscal 2025, bringing in $41.93M of $76.20M (55%).
| Counterparty Name | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | $9.14M | $49.30M | $77.96M | $41.93M | |||||||
| Bristol Myers Squibb Company | — | — | — | — | |||||||
| Astellas Pharma Inc | $20.49M | $24.45M | $29.38M | $17.91M | |||||||
| Abbvie Ireland Unlimited Company | $18.56M | $3.69M | — | — | |||||||
| Modernatx, Inc | — | $10.84M | $16.88M | $31.00K | |||||||
| Regeneron Pharmaceuticals, Inc | — | $7.19M | $10.83M | $6.51M | |||||||
| Immuno Gen Inc | — | — | — | — | |||||||
| Amgen Inc | $4.97M | $5.74M | $3.05M | $9.82M | |||||||
| Pfizer Inc | — | — | — | — | |||||||
| Total | $53.16M | $101.21M | $138.10M | $76.20M |
CytomX Therapeutics brought in $76.20M from its five revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 44.8% from $138.10M in fiscal 2024. Bristol Myers Squibb was the largest at $41.93M (55.0%), ahead of Astellas Pharma Inc at $17.91M (23.5%) and Amgen Inc at $9.82M (12.9%). The other two revenue lines brought in $6.54M combined.
Compared with fiscal 2024, Amgen Inc grew fastest, up 221.5% to $9.82M, while Bristol Myers Squibb fell the most, down 46.2% to $41.93M.
CytomX Therapeutics began breaking out Modernatx, Inc in fiscal 2023 and Regeneron Pharmaceuticals, Inc in fiscal 2023. CytomX Therapeutics stopped reporting Abbvie Ireland Unlimited Company as a separate revenue line after fiscal 2023, when it brought in $3.69M.
Previously Reported was CytomX Therapeutics’s largest revenue line in fiscal 2021, bringing in $69.57M of $37.31M (186%).
| Revision of Prior Period | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|
| Previously Reported | $57.49M | $100.36M | $69.57M |
| Restatement Adjustment | -$30.59M | -$31.90M | -$32.26M |
| Total | $26.90M | $68.46M | $37.31M |
CytomX Therapeutics brought in $37.31M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. That was down 45.5% from $68.46M in fiscal 2020. Previously Reported was the largest at $69.57M (186.5%).
From fiscal 2019 to 2021, combined revenue from these revenue lines grew from $26.90M to $37.31M, a compound annual growth rate of 17.8%. Previously Reported's share of the total fell from 213.7% to 186.5%.
The total is net of Restatement Adjustment, which took $32.26M off revenue in fiscal 2021.
CytomX Therapeutics (CTMX) reports its revenue by counterparty name and by revision of prior period. In fiscal 2025, Bristol Myers Squibb was its largest revenue line, bringing in $41.93M (55.0% of the total), followed by Astellas Pharma Inc at $17.91M (23.5%).
Bristol Myers Squibb was CytomX Therapeutics' largest revenue line in fiscal 2025, bringing in $41.93M, or 55.0% of the $76.20M total across its five revenue lines.
Among CytomX Therapeutics' revenue lines that make up at least 2% of revenue, Amgen Inc grew fastest in fiscal 2025, up 221.5% from $3.05M to $9.82M.
Every figure comes from CytomX Therapeutics' annual financial filings, as reported. Each line keeps the name CytomX Therapeutics gives it, and years follow its fiscal calendar.
CytomX Therapeutics' revenue by counterparty name goes back to fiscal 2015, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.